Definiens has released the latest version of its image analysis application Definiens TissueMap 3.0.
The application quantitatively assesses cellular structures and substructures in whole tissue sections and tissue microarrays, helping researchers discover, validate and measure new drug targets and disease-specific biomarkers.
The discovery of biomarker models and the increasing use of imaging technologies to acquire accurate measurements of disease parameters are significantly impacting the drug development process. However, the detailed quantification of key parameters, which is largely performed manually, remains a time-consuming and often inconsistent process.
Definiens TissueMap 3.0 accelerates image analysis by automatically identifying and quantifying nuclear, cytoplasmic and membrane markers in epithelial tumors and xenografts, providing researchers with fast, accurate and reproducible results. The application can handle both whole section slides and tissue microarrays and can differentiate between viable and necrotic tissue in xenografts. Implementing automated image analysis enables biotechnology and pharmaceutical companies to improve the prioritization of quality drug candidates by identifying poor candidates earlier in the drug development process and thereby realize substantial cost savings.
Definiens TissueMap 3.0 comes with a set of pre-defined tools to detect and quantify specific morphological or functional structures in tissues, such as tumor sections. The application is built on Definiens XD, Definiens’ multidimensional image analysis platform, which is flexible, scalable and supports a wide range of image acquisition devices.
